Peptide Profile

Humanin

Mitochondrial-Derived Peptide

Research Only10 sourcesShop Humanin

Overview

Composition

Small mitochondrial-derived peptide (MDP) consisting of 24 amino acids (sequence: MAPRGFSCLLLLTSEIDLPVKRRA), encoded within the 16S ribosomal RNA gene (MT-RNR2) of the mitochondrial genome

Mechanism of Action

Functions as a cytoprotective factor, inhibiting apoptosis (programmed cell death), reducing oxidative stress, preserving mitochondrial integrity, and modulating inflammation

Primary Effects

Studied for cytoprotective effects in neuronal, cardiac, and metabolic models; observational work links endogenous levels with age- and stress-related phenotypes

Discovery & Background

Discovered in 2001 by multiple independent research groups, most notably the Nishimoto lab, during a functional screening of cDNA from the relatively spared occipital lobe of an Alzheimer's disease patient's brain

Identified as a factor that rescued neuronal cells from amyloid-beta-induced toxicity and apoptosis linked to Alzheimer's pathology; additional groups found it through interactions with pro-apoptotic proteins like Bax and IGFBP-3; as the first identified mitochondrial-derived peptide with systemic activity, Humanin opened a new class of bioactive molecules encoded by mitochondrial short open reading frames (sORFs)

Primarily a research compound; no large-scale clinical approvals exist; interventional human trials remain absent or extremely limited

Research Overview

Preclinical studies (in vitro cell cultures, rodent models, and other animals) dominate the evidence base, demonstrating Humanin's cytoprotective roles

01
Neuroprotection in models of neurodegeneration (e.g., Alzheimer's, Parkinson's)
02
Cardiovascular stress protection (ischemia/reperfusion injury)
03
Metabolic disorder benefits (diabetes, insulin resistance)
04
Aging-related endpoints include lifespan or healthspan signals in C. elegans and mice
05
Analogs such as HNG (S14G-Humanin) show greater activity in selected assays
06
Human observational data link higher endogenous levels to better healthspan, slower cognitive aging, and protection against age-related diseases
07
Lower levels in conditions like Alzheimer's

No large-scale clinical approvals; human efficacy data are scarce

Safety Considerations

Monitoring

Cognitive function
Cardiovascular markers
Metabolic parameters
Energy levels
Overall well-being

Side Effects

Common

Generally well-tolerated in preclinical reports
No standardized human adverse-event profile has been established
Flu-like symptoms occasionally noted

Context-Dependent

Endogenous Humanin appears safe
Exogenous effects may vary by context (e.g., sex-dependent in some models)

Contraindications

Limited data; caution in metabolic disorders or with glucose-altering agents
No FDA approval or extensive human clinical validation for therapeutic use

Educational Notice

Humanin is best framed as a mitochondrial-derived peptide research topic rather than an established therapy. Preclinical and observational evidence covers neurodegeneration, cardiovascular biology, metabolism, and aging pathways, but it lacks FDA approval and extensive interventional human validation. Clinical decisions require qualified medical oversight.

References